Renal albumin excretion: Twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism

Hypertension

Volumn 49, Issue 5, 2007, Pages 1015-1031

  Rao, Fangwen ^a   Wessel, Jennifer ^b,e   Wen, Gen ^a   Zhang, Lian ^a   Rana, Brinda K ^b,e   Kennedy, Brian P ^a   Greenwood, Tiffany A ^b,e   Salem, Rany M ^a   Chen, Yuqing ^a   Khandrika, Srikrishna ^a   Hamilton, Bruce A ^a   Smith, Douglas W ^b,e   Holstein Rathlou, Niels Henrik ^c   Ziegler, Michael G ^a   Schork, Nicholas J ^b,d,e   O'Connor, Daniel T ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Adrenergic; Catecholamine; Glomerulus; Hypertension; Inflammation; Metabolic; Receptor

Indexed keywords

ADRENALIN; ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHROMOGRANIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE 1 RECEPTOR; NORADRENALIN; POTASSIUM; PROTEIN TYROSINE KINASE; RHO KINASE; SODIUM; ADRENERGIC RECEPTOR; CATECHOLAMINE;

ADRENERGIC SYSTEM; ADULT; ARTICLE; ELECTROLYTE EXCRETION; ELECTROLYTE INTAKE; EPISTASIS; FEMALE; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HERITABILITY; HUMAN; HYPERTENSION; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TWINS; ADOLESCENT; AGED; ALBUMINURIA; BIOSYNTHESIS; ENVIRONMENT; EXOCYTOSIS; GENETIC EPISTASIS; GENETIC POLYMORPHISM; GENETICS; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; CATECHOLAMINES; ENVIRONMENT; EPISTASIS, GENETIC; EXOCYTOSIS; FEMALE; HAPLOTYPES; HUMANS; KIDNEY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE D1; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 34247880260     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.106.081679     Document Type: Article

References (51)

1. Yuyun MF, Adler AI, Wareham NJ. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin Nephrol Hypertens. 2005;14:271-276.
2. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The nord-trondelag health study (hunt), Norway. Am J Kidney Dis. 2003;42:466-473.
3. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32-35.
4. Guyton AC. Blood pressure control - special role of the kidneys and body fluids. Science. 1991;252:1813-1816.
5. King SE, Baldwin DS. Production of renal ischemia and proteinuria in man by the adrenal medullary hormones. Am J Med. 1956;20:217-224.
6. Freedman BI, Beck SR, Rich SS, Heiss G, Lewis CE, Turner S, Province MA, Schwander KL, Arnett DK, Mellen BG. A genome-wide scan for urinary albumin excretion in hypertensive families. Hypertension. 2003;42:291-296.
7. Zhang L, Rao F, Wessel J, Kennedy BP, Rana BK, Taupenot L, Lillie EO, Cockburn M, Schork NJ, Ziegler MG, O'Connor DT. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics. 2004;19:277-291.
8. Sharma P, Hingorani A, Jia H, Ashby M, Hopper R, Clayton D, Brown MJ. Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension. 1998;32:676-682.
9. Lee YW, Oh VM, Garcia E, Taylor EA, Wu H, Yap EP, Kazeem GR, Caulfield MJ, Munroe PB. Haplotypes of the beta2-adrenergic receptor gene are associated with essential hypertension in a Singaporean Chinese population. J Hypertens. 2004;22:2111-2116.
10. Ranade K, Shue WH, Hung YJ, Hsuing CA, Chiang FT, Pesich R, Hebert J, Olivier M, Chen YD, Pratt R, Olshen R, Curb D, Botstein D, Risch N, Cox DR. The glycine allele of a glycine/arginine polymorphism in the beta2-adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin. Am J Hypertens. 2001;14:1196-1200.
11. Bao X, Mills PJ, Rana BK, Dimsdale JE, Schork NJ, Smith DW, Rao F, Milic M, O'Connor DT, Ziegler MG. Interactive effects of common beta2-adrenoceptor haplotypes and age on susceptibility to hypertension and receptor function. Hypertension. 2005;46:301-307.
12. Boomsma D, Busjahn A, Peltonen L. Classical twin studies and beyond. Nat Rev Genet. 2002;3:872-882.
13. MacGregor AJ, Snieder H, Schork NJ, Spector TD. Twins. Novel uses to study complex traits and genetic diseases. Trends Genet. 2000;16:131-134.
14. Falconer DS, Mackay TFC. Introduction to Quantitative Genetics. Harlow, London, UK: Longman; 1996.
15. Almasy L, Dyer TD, Blangero J. Bivariate quantitative trait linkage analysis: pleiotropy versus co-incident linkages. Genet Epidemiol. 1997;14:953-958.
16. Cockburn M, Hamilton A, Zadnick J, Cozen W, Mack TM. The occurrence of chronic disease and other conditions in a large population-based cohort of native californian twins. Twin Res. 2002;5:460-467.
17. O'Connor DT, Insel PA, Ziegler MG, Hook VY, Smith DW, Hamilton BA, Taylor PW, Parmer RJ. Heredity and the autonomic nervous system in human hypertension. Curr Hypertens Rep. 2000;2:16-22.
18. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002;20:1335-1345.
19. Herrmann V, Buscher R, Go MM, Ring KM, Hofer JK, Kailasam MT, O'Connor DT, Parmer RJ, Insel PA. Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens. 2000;13:1021-1026.
20. Seasholtz TM, Wessel J, Rao F, Rana BK, Khandrika S, Kennedy BP, Lillie EO, Ziegler MG, Smith DW, Schork NJ, Brown JH, O'Connor DT. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension. 2006;47:937-947.
21. Greenwood TA, Rao F, Stridsberg M, Mahapatra NR, Mahata M, Lillie EO, Mahata SK, Taupenot L, Schork NJ, O'Connor DT. Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. Physiol Genomics. 2006;25:470-479.
22. Brinton TJ, Kailasam MT, Wu RA, Cervenka JH, Chio SS, Parmer RJ, DeMaria AN, O'Connor DT. Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk. Hypertension. 1996;28:599-603.
23. Rosenberg NA, Nordborg M. Genealogical trees, coalescent theory and the analysis of genetic polymorphisms. Nat Rev Genet. 2002;3:380-390.
24. Halperin E, Eskin E. Haplotype reconstruction from genotype data using imperfect phylogeny. Bioinformatics. 2004;20:1842-1849.
25. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. Hypertension from targeted ablation of chromogranin a can be rescued by the human ortholog. J Clin Invest. 2005;115:1942-1952.
26. Taupenot L, Harper KL, O'Connor DT. Role of h+-atpase-mediated acidification in sorting and release of the regulated secretory protein chromogranin a: evidence for a vesiculogenic function. J Biol Chem. 2005;280:3885-3897.
27. Zheng B, Ma YC, Ostrom RS, Lavoie C, Gill GN, Insel PA, Huang XY, Farquhar MG. Rgs-px1, a gap for galphas and sorting nexin in vesicular trafficking. Science. 2001;294:1939-1942.
28. Blangero J, Williams JT, Almasy L. Variance component methods for detecting complex trait loci. Adv Genet. 2001;42:151-181.
29. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet. 2002;11:2463-2468.
30. Moore JH, Hahn LW. A cellular automata approach to detecting interactions among single-nucleotide polymorphisms in complex multifactorial diseases. Pac Symp Biocomput. 2002;7:53-64.
31. Comings DE, MacMurray JP. Molecular heterosis: a review. Mol Genet Metab. 2000;71:19-31.
32. Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B. Genetic variation at the ace gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the dcct/edic genetics study. Diabetes. 2005;54:1238-1244.
33. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-1149.
34. Kim T, Loh YP. Chromogranin a: a surprising link between granule biogenesis and hypertension. J Clin Invest. 2005;115:1711-1713.
35. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest. 1997;100:1623-1633.
36. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, O'Connor DT. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol. 2004;66:1180-1191.
37. O'Connor DT, Cadman PE, Smiley C, Salem RM, Rao F, Smith J, Funk SD, Mahata SK, Mahata M, Wen G, Taupenot L, Gonzalez-Yanes C, Harper KL, Henry RR, Sanchez-Margalet V. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab. 2005;90:5414-5425.
38. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, Rao F, Stridsberg M, Smith DW, Mahboubi P, Schork NJ, O'Connor DT, Hamilton BA. Both rare and common polymorphisms contribute functional variation at chga, a regulator of catecholamine physiology. Am J Hum Genet. 2004;74:197-207.
39. Quinones H, Collazo R, Moe OW. The dopamine precursor l-dihydroxyphenylalanine is transported by the amino acid transporters rbat and lat2 in renal cortex. Am J Physiol Renal Physiol. 2004;287:F74-F80.
40. Jose PA, Eisner GM, Felder RA. Dopamine and the kidney: a role in hypertension? Curr Opin Nephrol Hypertens. 2003;12:189-194.
41. Endlich N, Endlich K. Camp pathway in podocytes. Microsc Res Tech. 2002;57:228-231.
42. Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol. 1998;9:1759-1766.
43. Rump LC, Schwertfeger E, Schuster MJ, Schaible U, Frankenschmidt A, Schollmeyer PJ. Dopamine da2-receptor activation inhibits noradrenaline release in human kidney slices. Kidney Int. 1993;43:197-204.
44. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62:1198-1211.
45. Cockburn MG, Hamilton AS, Zadnick J, Cozen W, Mack TM. Development and representativeness of a large population-based cohort of native californian twins. Twin Res. 2001;4:242-250.
46. Do KA, Broom BM, Kuhnert P, Duffy DL, Todorov AA, Treloar SA, Martin NG. Genetic analysis of the age at menopause by using estimating equations and bayesian random effects models. Stat Med. 2000;19:1217-1235.
47. Visscher PM, Duffy DL. The value of relatives with phenotypes but missing genotypes in association studies for quantitative traits. Genet Epidemiol. 2006;30:30-36.
48. Knowler WC, Williams RC, Pettitt DJ, Steinberg AG. Gm3;5, 13, 14 and type 2 diabetes mellitus: an association in american indians with genetic admixture. Am J Hum Genet. 1988;43:520-526.
49. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516-1517.
50. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;11:1469-1478.
51. Cadman PE, O'Connor DT. Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens. 2003;12:61-70.